NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vial

Land: Australien

Sprog: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv bestanddel:

nelarabine, Quantity: 250 mg

Tilgængelig fra:

Reach Pharmaceuticals Pty Ltd

Lægemiddelform:

Injection, solution

Sammensætning:

Excipient Ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections

Indgivelsesvej:

Intravenous Infusion

Enheder i pakken:

6, 1

Recept type:

(S4) Prescription Only Medicine

Terapeutiske indikationer:

Nelarabine is indicated for the treatment of patients with relapsing /refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment.,Due to the small patient populations in these disease settings, the information to support these indications is based on limited data..

Produkt oversigt:

Visual Identification: Clear colourless solution.; Container Type: Vial; Container Material: Glass; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Autorisation status:

Registered